🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Beth Overmoyer

ORCID: 0000-0003-4438-7000
Biochemistry, Genetics and Molecular BiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 6%percentile
0.329Author DataRank

Indexed papers

4in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology
Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 4 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Top data-sharing exemplar

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Development of a multi-institutional dataset to validate a novel inflammatory breast cancer diagnostic score

JNCI Journal of the National Cancer Institute(2025)10.1093/jnci/djaf088
Top 52%
0.329DataRank
Top 52%7 citations

Samuel M. Niman, Megumi Kai, Sean G. Ryan, Elizabeth Troll, Li Li +16 more

Papers

Driven by 14 papers — median percentile 0. Top paper: “Pembrolizumab in brain metastases of diverse histologies: phase 2 trial results”.

Pembrolizumab in brain metastases of diverse histologies: phase 2 trial results

Nature Medicine(2023)10.1038/s41591-023-02392-7
N/A
1.6DataRank · unranked
66 citations

Albert E. Kim, Anita Giobbie‐Hurder, Eudocia Q. Lee, Nancy U. Lin, Beth Overmoyer +28 more

Phase Ib study of pembrolizumab in combination with trastuzumab emtansine for metastatic HER2-positive breast cancer

Journal for ImmunoTherapy of Cancer(2022)10.1136/jitc-2022-005119
N/A
1.2DataRank · unranked
39 citations

Tanya E. Keenan, Tianyu Li, Nabihah Tayob, Gerburg M. Wulf, Edward T. Richardson +10 more

The feasibility of using an autologous GM-CSF-secreting breast cancer vaccine to induce immunity in patients with stage II–III and metastatic breast cancers

Breast Cancer Research and Treatment(2022)10.1007/s10549-022-06562-y
N/A
0.750DataRank · unranked
23 citations

Timothy K. Erick, Meixuan Chen, Heather Daley, Margaret Campbell, Yolonda L. Colson +8 more

Early on-treatment transcriptional profiling as a tool for improving pathological response prediction in HER2-positive inflammatory breast cancer

Therapeutic Advances in Medical Oncology(2022)10.1177/17588359221113269
N/A
0.672DataRank · unranked
15 citations

Jennifer L. Guerriero, Sergey Naumenko, Shom Goel, Meredith M. Regan, Jiani Hu +10 more

Clinical Efficacy and Molecular Response Correlates of the WEE1 Inhibitor Adavosertib Combined with Cisplatin in Patients with Metastatic Triple-Negative Breast Cancer

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-3089
N/A
0.596DataRank · unranked
52 citations

Tianyu Li, Tuulia Vallius, Jennifer L. Guerriero, Nabihah Tayob, Bose Kochupurakkal +17 more

Nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer: a phase II and biomarker study

npj Breast Cancer(2021)10.1038/s41523-021-00287-9
N/A
0.593DataRank · unranked
51 citations

Tanya E. Keenan, Tianyu Li, Nabihah Tayob, Lorenzo Trippa, Ricardo Pastorello +11 more

Development of a multi-institutional dataset to validate a novel inflammatory breast cancer diagnostic score

JNCI Journal of the National Cancer Institute(2025)10.1093/jnci/djaf088
Top 52%
0.329DataRank
Top 52%7 citations

Samuel M. Niman, Megumi Kai, Sean G. Ryan, Elizabeth Troll, Li Li +16 more

Abnormal vascular structure and function within brain metastases is linked to pembrolizumab resistance

Neuro-Oncology(2023)10.1093/neuonc/noad236
N/A
0.323DataRank · unranked
6 citations

Kevin W Lou, Anita Giobbie‐Hurder, Ken Chang, Mishka Gidwani, Katharina Hoebel +38 more

Copy Number Variation in Inflammatory Breast Cancer

Cells(2023)10.3390/cells12071086
N/A
0.269DataRank · unranked
5 citations

Andrea O’Hara, Kornelia Polyak, Faina Nakhlis, Beth T. Harrison, Antonio Giordano +3 more

Data from Clinical Efficacy and Molecular Response Correlates of the WEE1 Inhibitor Adavosertib Combined with Cisplatin in Patients with Metastatic Triple-Negative Breast Cancer

(2023)10.1158/1078-0432.c.6530060.v1
Top 100%
0DataRank
Top 100%0 citations

Tianyu Li, Tuulia Vallius, Jennifer L. Guerriero, Nabihah Tayob, Bose Kochupurakkal +17 more

Data from Clinical Efficacy and Molecular Response Correlates of the WEE1 Inhibitor Adavosertib Combined with Cisplatin in Patients with Metastatic Triple-Negative Breast Cancer

(2023)10.1158/1078-0432.c.6530060
Top 100%
0DataRank
Top 100%0 citations

Tianyu Li, Tuulia Vallius, Jennifer L. Guerriero, Nabihah Tayob, Bose Kochupurakkal +17 more

Structural and functional vascular dysfunction within brain metastases is linked to pembrolizumab inefficacy

bioRxiv (Cold Spring Harbor Laboratory)(2023)10.1101/2023.08.25.554868
N/A
0DataRank · unranked
0 citations

Kevin W Lou, Anita Giobbie‐Hurder, Ken Chang, Mishka Gidwani, Katharina Hoebel +38 more

Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II–III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance)

UNC Libraries(2020)10.17615/3qn5-sn85
N/A
0DataRank · unranked
0 citations

Lisa A. Carey, Beth Overmoyer, Constance Cirrincione, William M. Sikov, Mehra Golshan +9 more

Chemotherapy-related amenorrhea after adjuvant paclitaxel–trastuzumab (APT trial)

UNC Libraries(2020)10.17615/e33z-ag80
N/A
0DataRank · unranked
0 citations

Harold J. Burstein, Lisa A. Carey, Antonio C. Wolff, Sara M. Tolaney, P. Kelly Marcom +15 more